TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
On Wednesday, Chardan Capital Markets commenced coverage on shares of Tourmaline Bio (NASDAQ:TRML), assigning a Buy rating to the biotechnology firm. The research firm set a price target of $70.00 for Tourmaline Bio’s stock, indicating confidence in the company’s growth prospects. Currently trading at $17.32, the stock has significant upside potential according to analyst consensus, with targets ranging from $43 to $65. InvestingPro data shows the stock has already gained over 19% in the past week.
The optimism from Chardan Capital Markets stems from the potential of Tourmaline Bio’s primary product candidate, an anti-IL6 antibody named pacibekitug (TOUR006). This drug is currently being developed for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). Chardan analysts also noted the additional upside potential for pacibekitug in treating abdominal aortic aneurysm (AAA). InvestingPro analysis reveals the company maintains a strong financial health score of 2.67, with more cash than debt on its balance sheet.
The coverage initiation by Chardan Capital Markets highlights the company’s strategic position in the biotech industry, with a focus on the development of its lead asset. The Buy rating reflects the firm’s belief in the commercial viability and therapeutic efficacy of pacibekitug in its targeted diseases.
Tourmaline Bio’s stock price target of $70.00 by Chardan Capital Markets is based on the anticipated success and market penetration of pacibekitug. The therapy’s progress in clinical trials and potential regulatory approvals will be critical milestones for the company as it seeks to establish a strong presence in the market for treatments for TED, ASCVD, and potentially AAA. Investors should note that the company is rapidly burning through cash, with the next earnings report due on May 8. Get deeper insights and access to 8 additional ProTips with InvestingPro.
The initiation of coverage by Chardan Capital Markets is a significant development for Tourmaline Bio, providing investors with an analysis of the company’s prospects. The Buy rating and price target are indicators of the research firm’s expectations for the stock’s performance, based on the current assessment of Tourmaline Bio’s lead asset and its potential impact on the company’s future.
In other recent news, Tourmaline Bio has reported its fourth-quarter and full-year financial results for 2024, revealing a net loss of $22.2 million, or ($0.86) per share, slightly above the estimated loss of $21.1 million. The full-year net loss amounted to $73.2 million, or ($2.89) per share. Meanwhile, Truist Securities has adjusted its price target for Tourmaline Bio to $63 from the previous $74, maintaining a Buy rating due to its optimistic outlook on the company’s cardiovascular treatment, Pacibekitug. H.C. Wainwright has also raised its price target for Tourmaline Bio to $50, up from $49, while keeping a Buy rating following the financial results announcement.
The ongoing Phase 2 TRANQUILITY trial for Pacibekitug, involving 143 patients, is a significant focus, with topline data expected in the second quarter of 2025. Analysts from Truist Securities and H.C. Wainwright have highlighted the trial as a potential catalyst for the company, with pharmacokinetic and pharmacodynamic modeling suggesting promising reductions in inflammation markers. Additionally, the anticipated Phase 3 ZEUS trial data for Novo Nordisk (NYSE:NVO)’s ziltivekimab, another IL-6 inhibitor, is expected to offer valuable insights into the treatment of ASCVD. Both Truist Securities and H.C. Wainwright see potential strategic partnerships as key opportunities for Tourmaline Bio. The company’s stock is seen as an attractive investment, trading near its cash value, which could benefit from upcoming clinical trial data and strategic developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.